{"id":55590,"date":"2024-02-07T05:32:09","date_gmt":"2024-02-07T05:32:09","guid":{"rendered":"https:\/\/medsname.com\/atomoxet\/"},"modified":"2026-04-30T10:24:46","modified_gmt":"2026-04-30T10:24:46","slug":"atomoxet","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/atomoxet\/","title":{"rendered":"Atomoxet"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f<\/h3>\n

Atomoxet (Atomoxetine 10 \/ 18 \/ 25 \/ 40 \/ 60 \/ 80 mg) is a selective noradrenaline reuptake inhibitor for ADHD in children, adolescents, and adults. Non-stimulant \u2014 no abuse potential, no controlled-substance scheduling. Useful when stimulants are unsuitable, ineffective, or contraindicated.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Atomoxet at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a> \u2014 20pracovn\u00edchdenn\u00ed lh\u016fta pro doru\u010den\u00ed, nebo v\u00e1m z\u00e1silku zdarma p\u0159epo\u0161leme \u2014 a oprav\u0148uje v\u00e1s k \u00fa\u010dasti v na\u0161em v\u011brnostn\u00edm programu<\/a>. Dod\u00e1v\u00e1me do v\u011bt\u0161iny zem\u00ed po cel\u00e9m sv\u011bt\u011b.<\/p>\n

What Atomoxet is and how it works<\/h2>\n

Atomoxet is a 10 \/ 18 \/ 25 \/ 40 \/ 60 \/ 80 mg atomoxetine capsule supplied by Intas. Atomoxetine selectively inhibits the noradrenaline reuptake transporter (NET), increasing synaptic noradrenaline and \u2014 indirectly via cortical NA-DA crosstalk \u2014 frontal-cortex dopamine, without affecting striatal dopamine. The latter is what differentiates atomoxetine from stimulants: no euphoria, no abuse potential, no controlled-substance scheduling.<\/p>\n

\nSlow onset \u2014 not a same-day medication<\/strong><\/p>\n

Stimulants work within 30\u201360 minutes of the first dose. Atomoxetine takes 2\u20134 weeks for initial response and 8\u201312 weeks for full effect. Patients (and parents) expecting stimulant-like immediate change will be disappointed and discontinue. Set the expectation at initiation.<\/p>\n<\/div>\n

Indikace a d\u00e1vkov\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n\n
Pacient<\/th>\nPo\u010d\u00e1te\u010dn\u00ed d\u00e1vka<\/th>\nC\u00edlov\u00e1 d\u00e1vka<\/th>\nMaxim\u00e1ln\u00ed d\u00e1vka<\/th>\n<\/tr>\n<\/thead>\n
Children & adolescents \u2264 70 kg<\/td>\n0.5 mg\/kg\/day \u00d7 3 d<\/td>\n1.2 mg\/kg\/day<\/td>\n1.4 mg\/kg or 100 mg<\/td>\n<\/tr>\n
Children & adolescents > 70 kg<\/td>\n40 mg OD \u00d7 3 d<\/td>\n80 mg OD<\/td>\n100 mg OD<\/td>\n<\/tr>\n
Dosp\u011bl\u00ed<\/td>\n40 mg OD \u00d7 7 d<\/td>\n80 mg OD<\/td>\n100 mg<\/td>\n<\/tr>\n
Strong CYP2D6 inhibitor \/ poor metaboliser<\/td>\n0.5 mg\/kg or 40 mg<\/td>\n0.5 \u00d7 normal target<\/td>\nby tolerability<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Can be given once daily morning or split BID (morning + late afternoon \u2014 avoid evening because of insomnia).<\/p>\n

D\u016fle\u017eit\u00e9 bezpe\u010dnostn\u00ed aspekty<\/h2>\n
\nSuicidality black-box (paediatric)<\/strong><\/p>\n

Atomoxetine carries an FDA black-box warning for increased suicidal ideation in children and adolescents, particularly in the first month and at dose changes. Monitor closely for behaviour change in paediatric patients on initiation.<\/p>\n<\/div>\n

\nHepatotoxicity \u2014 rare<\/strong><\/p>\n

Rare cases of severe hepatic injury have been reported. Stop immediately if jaundice, dark urine, RUQ pain, fatigue, or unexplained nausea appear. Do not restart after definite hepatic injury.<\/p>\n<\/div>\n

\nKardiovaskul\u00e1rn\u00ed<\/strong><\/p>\n

Atomoxetine produces small mean increases in BP (+2 mmHg) and HR (+5 bpm). Greater rises occasionally seen in adults. Check BP and HR at baseline, at each dose change, and at follow-up. Avoid in serious cardiac structural abnormality, severe cardiovascular disease, or pheochromocytoma.<\/p>\n<\/div>\n

\nGrowth (paediatric)<\/strong><\/p>\n

Mild reductions in growth velocity reported in children on atomoxetine \u2014 usually catch up over time. Plot height and weight at every visit.<\/p>\n<\/div>\n

\u010cast\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky<\/h2>\n